Integra Lifesciences Holdings (IART) Operating Expenses (2009 - 2026)

Integra Lifesciences Holdings has disclosed Operating Expenses across 18 years of filings, most recently posting $399.5 million for Q2 2026.

• In Q2 2026, Operating Expenses fell 56.97% year-over-year to $399.5 million; the TTM figure through Jun 2026 stood at $1.6 billion (down 25.46% YoY), while the FY2025 annual figure was $2.1 billion, up 34.54% from the prior year.
• Operating Expenses came in at $399.5 million for Q2 2026 at Integra Lifesciences Holdings, up from $380.4 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $928.3 million in Q2 2025 to a low of $320.1 million in Q3 2022.
• Average Operating Expenses over 5 years is $402.2 million, with a median of $374.6 million recorded in 2023.
• Year-over-year, Operating Expenses soared 120.39% in 2025 and slumped 56.97% in 2026.
• Over 5 years, Operating Expenses stood at $330.2 million in 2022, then rose by 9.33% to $361.0 million in 2023, then increased by 12.75% to $407.0 million in 2024, then advanced by 1.2% to $411.9 million in 2025, then slipped by 3.01% to $399.5 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $399.5 million in Q2 2026, $380.4 million in Q1 2026, and $411.9 million in Q4 2025.